Рет қаралды 345
Tags: Cannabis Law, FDA, Pharmaceuticals, Regulations
Ms. Mead, Vice President, U.S. Public Policy and Public Affairs, for Greenwich Biosciences (one of the first companies in the world to develop cannabis-derived medications as prescription products in adherence to modern scientific and regulatory standards for pharmaceutical products), discusses how the challenges of securing approval from the Food & Drug Association (FDA) are even greater for products derived from botanical materials.